Targeting glucose metabolism to suppress cancer progression: prospective of anti-glycolytic cancer therapy - Abdel-Wahab, Ali F.; Mahmoud, Waheed; Al-Harizy, Randa M. (Pharmacological research, 2019)
Keywords: Aerobic glycolysis; Antiglycolytic agents; Cancer therapy; Warburg effect; 3-Bromopyruvate (PubChem CID: 70684); LN; Dichloroacetate (PubChem CID: 517326); OxPhos; ENO1; H2O2; G-6-P; HK2; PI3K; Rapamycin (PubChem CID: 5284616); mTOR; PFK1; PFKFB; PHGDH; 3-BrPA; TNBC; PK-M2; PDK1; Warburg effect; TKTL1; DCA; GLUTs; AMP; HCC; ERRα; EMT; GPx; Lonidamine (PubChem CID: 39562); PDAC; RCC; TCA; ß-CD–3BrPA; PGK; PGM; ROS; AMPK; GAPDH; mTORC1; Antiglycolytic agents; Oxamate (PubChem CID: 974); Fasentin (PubChem CID: 879520); mtDNA; Glo1; FDG; Phloretin (PubChem CID: 4788); PHD; EGFR; PPP; Metformin (PubChem CID: 4091); LDHA; OA; GBM; CAFs; PDH; HIF-1 α; NADP; GSH; Omeprazole (PubChem CID:4549); EGF; SGLT1; VEGF; 2-DG; F-2; siRNA; Koningic acid (PubChem CID: 124361); BET; NAD; ALDH; PFK15; 3PO; β-CD; ETC; DNA; PEL; Cancer therapy; Aerobic glycolysis; PEP; PK; ATP; HF; PET; MCT